

**2RT® Webinar Presentation by
Professor Robyn H. Guymer, MBBS, PhD**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, is pleased to advise that on 15 September 2022 at 12.00pm Eastern Australian time, Professor Robyn H. Guymer, MBBS, PhD will give a presentation on 2RT®, covering the clinical history of 2RT® and the potential clinical application of 2RT®. Professor Guymer will also discuss the planned Confirmatory Study.

Professor Guymer AM is the Deputy Director, Centre for Eye Research Australia (CERA) and Professor in the Department of Surgery (Ophthalmology), University of Melbourne, and Senior Medical Retinal Specialist, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia. She is one of the world's leading retinal experts and is well respected in the fields of both early and late-stage age-related macular degeneration or AMD. Professor Guymer was the Principal Investigator for the "LEAD" Study (Laser Intervention in Early-Stage Age related Macular Degeneration), conducted from 2012-2018 with follow up through to 2020, which showed the potential of 2RT® to delay the progression of AMD in a select sub-group of patients.

Professor Guymer will lead the planned Confirmatory Study, which aims to build on the findings from the LEAD Study.

According to Prof. Guymer, 2RT® addresses AMD in its intermediate stage unlike any other currently available device or pharmaceutical.

"I am pleased to be a part of this study. 2RT® addresses the disease in its earlier stages. No other device or pharmaceutical in the world does this," commented Prof. Guymer.

2RT® is a proprietary, world first nanosecond laser therapy to treat age-related macular degeneration in its intermediate stage. 2RT® works by stimulating the rejuvenation of cells in the retina to initiate a healing response that targets the underlying causes of AMD. 2RT® has the potential to transform the global treatment of AMD by treating patients earlier in the disease state. This represents a revolutionary change from the status quo and thereby provides enormous clinical and commercial potential.

AlpahRET is currently planning to partner to fund the Confirmatory Study.

Register in advance for the 2RT® webinar:

https://us06web.zoom.us/webinar/register/WN_6DK2w44RTAmZToYlz_zDqA

After registering, you will receive a confirmation email containing information about joining the webinar.

This release dated 9 September 2022 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
+61 417 818 658

tspurling@nova-eye.com

Company

Kate Hunt
Chief Commercial Officer
+61 404 080 679

khunt@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733

mflynn@nova-eye.com

ABOUT ALPHARET PTY LTD

AlphaRET Pty Ltd (AlphaRET) is a wholly owned subsidiary of Nova Eye Medical Limited. AlphaRET is focussed on executing the commercialization efforts for 2RT®

For additional information about AlphaRET and 2RT®, please visit:

www.alpha-RET.com

ABOUT NOVA EYE MEDICAL LIMITED

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include the iTrack™ portfolio of minimally invasive glaucoma surgery (MIGS) technologies, consumable surgical devices designed to restore the eye's natural outflow pathway to lower pressure inside the eye in patients with glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe or complex glaucoma. It also offers the benefit of a simplified and faster surgical profile. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by sales offices in Adelaide, Australia and Berlin, Germany, and a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:
www.nova-eye.com

DRAFT